Researchers at Northwestern Medicine have discovered why pancreatic cancer often resists immunotherapy: the tumor hides behind a “sugar coating” that tells the immune system not to attack. The study, published in Cancer Research in January 2026, also describes a new antibody designed to strip away this disguise.
Normally, healthy cells use a sugar called sialic acid to signal immune cells that they are harmless. Pancreatic cancer copies this trick by placing the sugar on a surface protein and binding to a sensor on immune cells, effectively sending a false “stand down” message. This allows the tumor to grow without being attacked.
After years of research, scientists developed an antibody that blocks this signal. In mouse studies, the antibody reactivated immune cells, slowed tumor growth, and helped the immune system destroy cancer cells. Researchers believe that combining this approach with chemotherapy or existing immunotherapies could potentially lead to complete tumor removal.
The team is now refining the antibody for human use and developing a test to identify patients most likely to benefit. They are also exploring whether the same immune-evasion strategy is used in other cancers, such as glioblastoma, though widespread clinical use is still estimated to be several years away.